Lupus Erythematosus (LUPUS)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 11 75 53 14 71 31 33
Lupus 11 19 41 2 14
Lupus Erythematosus, Systemic 71
Lupus Erythematosus, Discoid 71
Le - [lupus Erythematosus] 33
Subacute Cutaneous Lupus 71
Lupus Vulgaris 71


External Ids:

Disease Ontology 11 DOID:8857
ICD9CM 34 695.4
NCIt 49 C27153
SNOMED-CT 68 200936003
ICD10 31 L93
UMLS 71 C0024131 C0024138 C0024141 more

Summaries for Lupus Erythematosus

MedlinePlus: 41 What is lupus? Lupus is an autoimmune disease. This means that your immune system attacks healthy cells and tissues by mistake. This can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. There are several kinds of lupus: Systemic lupus erythematosus (SLE) is the most common type. It can be mild or severe and can affect many parts of the body. Discoid lupus causes a red rash that doesn't go away Subacute cutaneous lupus causes sores after being out in the sun Drug-induced lupus is caused by certain medicines. It usually goes away when you stop taking the medicine. Neonatal lupus, which is rare, affects newborns. It is probably caused by certain antibodies from the mother. What causes lupus? The cause of lupus is unknown. Who is at risk for lupus? Anyone can get lupus, but women are most at risk. Lupus is two to three times more common in African American women than in white women. It's also more common in Hispanic, Asian, and Native American women. African American and Hispanic women are more likely to have severe forms of lupus. What are the symptoms of lupus? Lupus can have many symptoms, and they differ from person to person. Some of the more common ones are: Pain or swelling in joints Muscle pain Fever with no known cause Red rashes, most often on the face (also called the "butterfly rash") Chest pain when taking a deep breath Hair loss Pale or purple fingers or toes Sensitivity to the sun Swelling in legs or around eyes Mouth ulcers Swollen glands Feeling very tired Symptoms may come and go. When you are having symptoms, it is called a flare. Flares can range from mild to severe. New symptoms may appear at any time. How is lupus diagnosed? There is no specific test for lupus, and it's often mistaken for other diseases. So it may take months or years for a doctor to diagnose it. Your doctor may use many tools to make a diagnosis: Medical history Complete exam Blood tests Skin biopsy (looking at skin samples under a microscope) Kidney biopsy (looking at tissue from your kidney under a microscope) What are the treatments for lupus? There is no cure for lupus, but medicines and lifestyle changes can help control it. People with lupus often need to see different doctors. You will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). Which other specialists you see depends on how lupus affects your body. For example, if lupus damages your heart or blood vessels, you would see a cardiologist. Your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. Your doctor will develop a treatment plan to fit your needs. You and your doctor should review the plan often to be sure it is working. You should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. The goals of the treatment plan are to: Prevent flares Treat flares when they occur Reduce organ damage and other problems Treatments may include drugs to: Reduce swelling and pain Prevent or reduce flares Help the immune system Reduce or prevent damage to joints Balance the hormones Besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. Alternative treatments are those that are not part of standard treatment. At this time, no research shows that alternative medicine can treat lupus. Some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. You should talk to your doctor before trying any alternative treatments. How can I cope with lupus? It is important to take an active role in your treatment. It helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. It is also important to find ways to cope with the stress of having lupus. Exercising and finding ways to relax may make it easier for you to cope. A good support system can also help. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus and systemic lupus erythematosus 16, and has symptoms including rashes, pruritus and seizures. An important gene associated with Lupus Erythematosus is CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Trimethoprim and Sulfamethoxazole have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and t cells, and related phenotypes are homeostasis/metabolism and renal/urinary system

CDC: 2 Lupus is an autoimmune disease that causes inflammation in different parts of the body. An autoimmune disease occurs when the body's immune system attacks itself. Its symptoms can show up in many different ways, which sometimes makes it hard to diagnose. Lupus symptoms can range from mild to life threatening, so early diagnosis and treatment by a rheumatologist are important. A rheumatologist is a doctor who has additional training and experience in the diagnosis and treatment of arthritis, lupus, and other diseases of the joints, muscles, and bones.

Disease Ontology: 11 An autoimmune disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs.

Wikipedia: 75 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 17 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 2 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 4 Systemic Lupus Erythematosus 5
Systemic Lupus Erythematosus 6 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Systemic Lupus Erythematosus 9
Systemic Lupus Erythematosus 10 Systemic Lupus Erythematosus 11
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 13
Systemic Lupus Erythematosus 14 Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2753)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 33.6 TRIM21 TNFSF4 TLR5 STAT4 SSB SNRNP70
2 systemic lupus erythematosus 16 33.5 DNASE1L3 DNASE1 C4A C1QA
3 drug-induced lupus erythematosus 33.5 TRIM21 SSB
4 vitiligo-associated multiple autoimmune disease susceptibility 1 33.2 PTPN22 PDCD1 CTLA4 C4B
5 libman-sacks endocarditis 33.0 TRIM21 SNRNP70
6 c1q deficiency 32.9 C1QC C1QB C1QA
7 autoimmune disease 32.8 TRIM21 STAT4 PTPN22 PDCD1 FCGR2B DNASE1
8 systemic scleroderma 32.8 TRIM21 STAT4 SSB SNRNP70
9 exanthem 32.6 TRIM21 PDCD1 CTLA4
10 complement factor i deficiency 32.6 C4B C4A
11 mononeuritis multiplex 32.4 TRIM21 SSB
12 glomerulonephritis 32.4 C4B C4A C1QC C1QB C1QA
13 immunodeficiency due to a classical component pathway complement deficiency 32.3 C4B C4A C1QC C1QB C1QA
14 heart block, congenital 32.0 TRIM21 SSB SNRNP70
15 autoimmune hepatitis 31.9 PTPN22 PDCD1 CTLA4 C4A
16 immune deficiency disease 31.8 STAT4 PDCD1 DNASE1 CTLA4 CR2 C4A
17 thrombocytopenia 31.8 TRIM21 PTPN22 PDCD1 FCGR2B CTLA4
18 aseptic meningitis 31.7 CTLA4 C4B C4A
19 aphthous stomatitis 31.6 TRIM21 STAT4 SSB
20 primary biliary cholangitis 31.6 TRIM21 STAT4 SSB PDCD1 CTLA4
21 celiac disease 1 31.6 TLR5 STAT4 PTPN22 CTLA4
22 hypersensitivity reaction type iii disease 31.6 FCGR2B C4B C4A
23 behcet syndrome 31.5 STAT4 PTPN22 CTLA4 C4A
24 type 1 diabetes mellitus 31.4 PTPN22 PDCD1 CTLA4 C4A
25 temporal arteritis 31.3 TRIM21 PTPN22 PDCD1 CTLA4
26 common variable immunodeficiency 31.3 TNFSF4 FCGR2B CTLA4 CR2
27 scleritis 31.2 TNFSF4 PTPN22 CTLA4
28 diffuse scleroderma 31.2 TRIM21 SNRNP70 BANK1
29 limited scleroderma 31.1 TRIM21 STAT4 SSB SNRNP70 BANK1
30 mononeuropathy 31.1 TRIM21 SSB
31 lymphoid interstitial pneumonia 31.0 TRIM21 SSB SNRNP70 CTLA4 CR2
32 parotitis 30.9 TRIM21 SSB
33 second-degree atrioventricular block 30.8 TRIM21 SSB
34 granulomatous hepatitis 30.7 PDCD1 CTLA4
35 polyclonal hypergammaglobulinemia 30.7 TRIM21 CR2
36 xerophthalmia 30.7 TRIM21 SSB
37 dyskinesia of esophagus 30.6 TRIM21 SNRNP70
38 mikulicz disease 30.5 TRIM21 SSB
39 antisynthetase syndrome 30.5 TRIM21 SNRNP70
40 facial hemiatrophy 30.3 SNRNP70 BANK1
41 parotid disease 30.3 TRIM21 SSB
42 dacryoadenitis 30.2 TRIM21 SSB
43 complement component 5 deficiency 30.0 C4B C4A
44 oligoarticular juvenile idiopathic arthritis 29.9 STAT4 PTPN22
45 systemic lupus erythematosus 1 12.2
46 cutaneous lupus erythematosus 12.0
47 discoid lupus erythematosus 12.0
48 subacute cutaneous lupus erythematosus 11.9
49 lupus erythematosus tumidus 11.9
50 chilblain lupus 1 11.8

Graphical network of the top 20 diseases related to Lupus Erythematosus:

Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus


  • rashes

UMLS symptoms related to Lupus Erythematosus:

pruritus; seizures; exanthema; heliotrope rash; lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 BANK1 C1QA C1QB C1QC C4A C4B
2 no effect GR00402-S-2 10.18 BANK1 C1QC C4A C4B CR2 CTLA4

MGI Mouse Phenotypes related to Lupus Erythematosus:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 C1QA C1QB C1QC C4A C4B CR2
2 renal/urinary system MP:0005367 10.11 C1QA C4A C4B CR2 DNASE1 FCGR2B
3 immune system MP:0005387 10.06 BANK1 C1QA C4A C4B CR2 CTLA4
4 liver/biliary system MP:0005370 9.92 C4A C4B CTLA4 FCGR2B PDCD1 PTPN22
5 hematopoietic system MP:0005397 9.83 BANK1 C4A C4B CR2 CTLA4 DNASE1
6 mortality/aging MP:0010768 9.44 C1QA C4A C4B CR2 CTLA4 DNASE1

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Lenalidomide Approved Phase 4 191732-72-6 216326
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
Atorvastatin Approved Phase 4 134523-00-5 60823
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Simvastatin Approved Phase 4 79902-63-9 54454
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
23 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
24 Angiogenesis Inhibitors Phase 4
Rosuvastatin Calcium Phase 4 147098-20-2
Triamcinolone hexacetonide Phase 4
Triamcinolone diacetate Phase 4
Triamcinolone Acetonide Phase 4 6436
29 Vaccines Phase 4
30 Estrogens Phase 4
31 Hypoglycemic Agents Phase 4
32 Omega 3 Fatty Acid Phase 4
33 Hydroxycholecalciferols Phase 4
34 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
35 Estrogens, Conjugated (USP) Phase 4
36 Cholinergic Agents Phase 4
Dimethoate Phase 4 3082
38 Cholinesterase Inhibitors Phase 4
Methylprednisolone Acetate Phase 4 584547
40 Antiviral Agents Phase 4
41 Complement C3 Phase 4
42 Anthelmintics Phase 4
43 Immunosuppressive Agents Phase 4
44 Immunologic Factors Phase 4
45 Calcineurin Inhibitors Phase 4
46 Hypolipidemic Agents Phase 4
47 Lipid Regulating Agents Phase 4
48 Anticholesteremic Agents Phase 4
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
50 Alkylating Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 998)
# Name Status NCT ID Phase Drugs
1 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Unknown status NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
2 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 Metformin In Prevention Of Lupus Nephritis In High Risk Patients Unknown status NCT04145687 Phase 4 Metformin
7 A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus Completed NCT03098823 Phase 4 RAYOS;Prednisone
8 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Completed NCT01705977 Phase 4
9 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
10 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin
11 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
12 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
13 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
14 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
15 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
16 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
17 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
18 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
19 A Single Arm, 24 Weeks, Pilot Study of Belimumab In Treatment of Early Systemic Lupus Erythematosus Completed NCT04956484 Phase 4 Standard of care
20 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Completed NCT01753401 Phase 4 Acthar;Placebo;Steroid Drug
21 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
22 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
23 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
24 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
25 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
26 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
27 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
28 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Completed NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;standard dose of HCQ
29 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
30 Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis Completed NCT04146220 Phase 4 Prednisolone
31 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
32 Comparison Between Mycophenolate andCyclophosphamide in the Treatment of Lupus Nephritis Completed NCT04424602 Phase 4 cyclo phosphamide;mycophenolate
33 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
34 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
35 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
36 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
37 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
38 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
39 Pilot Trial of Belimumab in Early Lupus Recruiting NCT03543839 Phase 4
40 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
41 Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study Recruiting NCT04447053 Phase 4 Belimumab Injection [Benlysta]
42 A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT04908865 Phase 4 Belimumab;Standard therapy
43 Efficacy and Safety of Belimumab for Prevention of Disease Flares in SLE Patients With Low Disease Activity Recruiting NCT04515719 Phase 4
44 A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
45 Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study Recruiting NCT05207358 Phase 4 Rituximab;Mycophenolate Mofetil;Cyclophosphamide;Corticosteroids
46 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study Recruiting NCT03214731 Phase 4 Artesunate
47 Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Therapy of Pediatric Patients With Active Proliferative Lupus Nephritis: A Prospective, Randomized, Multicenter, Open-label, Parallel-arm Study Recruiting NCT05495893 Phase 4 Cyclophosphamide;Mycophenolate Mofetil
48 Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis. Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel
49 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Crossover Study Evaluating the Safety and Immunogenicity of the Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus Not yet recruiting NCT05559671 Phase 4
50 A Model to Early Predict the Response of Belimumab Treatment in the Patients With Systemic Lupus Erythematosus Not yet recruiting NCT04893161 Phase 4 Belimumab

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Chloroquine hydrochloride
chloroquine phosphate
Hydroxychloroquine Sulfate
Triamcinolone Acetonide
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

Organs/tissues related to Lupus Erythematosus:

MalaCards : Skin, Heart, T Cells, Kidney, Bone Marrow, Brain, B Cells

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 39255)
# Title Authors PMID Year
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab. 62 41
36430417 2022
Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial. 62 41
36359816 2022
Artificial neural network - an effective tool for predicting the lupus nephritis outcome. 41
36443678 2022
Vaccination, atherosclerosis and systemic lupus erythematosus. 53 62
19880570 2009
[Association of interleukin-18 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population]. 53 62
18683145 2008
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 53 62
17550096 2006
Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients. 53 62
16987709 2006
Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. 53 62
15825571 2005
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients. 53 62
12716380 2003
Catalytic heterogenity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. 53 62
11208354 2000
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. 53 62
10599336 1999
Mucocutaneous disease in Arabs with systemic lupus erythematosus: clinical expression and relevance to autoantibodies. 53 62
9863895 1998
Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. 53 62
7774062 1995
Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. 53 62
8311089 1994
Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. 53 62
7686561 1993
Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families. 53 62
1545698 1992
[Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms]. 53 62
1577600 1992
Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. 53 62
2317112 1990
Nitrogen dioxide and hospital length of stay and cost for systemic lupus erythematosus in Hunan, China. 62
36162573 2023
Systemic lupus erythematosus and cardiovascular disease. 62
35982610 2023
Effectiveness of custom-made functional foot orthoses versus flat cushioning insoles on pain in patients with systemic lupus erythematosus. 62
35786028 2023
Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. 62
36470882 2022
Merkel cell number and distribution, and CD200 expression in patients with lichen planopilaris and discoid lupus erythematosus. 62
36445269 2022
Single-cell transcriptome reveals immunopathological cell composition of skin lesions in subacute cutaneous lupus erythematosus. 62
36343898 2022
Cutaneous lupus erythematosus flare with vitiligo-like depigmentation following the AstraZeneca COVID vaccine. 62
36340858 2022
The history of lupus throughout the ages. 62
32380218 2022
Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis. 62
36148853 2022
Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. 62
36325952 2022
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence. 62
36243406 2022
Association between AhR in B cells and systemic lupus erythematosus with renal damage. 62
36327874 2022
Peripheral immunophenotypes associated with the flare in the systemic lupus erythematosus patients with low disease activity state. 62
36270468 2022
Expression of the miR-9-5p, miR-125b-5p and its target gene NFKB1 and TRAF6 in childhood-onset systemic lupus erythematosus (cSLE). 62
36177494 2022
Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies. 62
36169280 2022
Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus. 62
36453450 2022
A Boy Presenting with a Fever and Pancytopenia Diagnosed with Systemic Lupus Erythematosus without a Positive Anti-ds-DNA Antibody Result or Hypocomplementemia: A Case Report. 62
36420549 2022
Vitamin D Presented In Vitro Immunomodulatory Property on T Lymphocyte-Related Cytokines in Systemic Lupus Erythematosus. 62
36459355 2022
LncRNA IL21-AS1 interacts with hnRNPU protein to promote IL21 overexpression and aberrant differentiation of Tfh cells in systemic lupus erythematosus. 62
36447054 2022
Burden of Comorbidities Predicts 30-Day Rehospitalizations in Young Adult Medicare Beneficiaries With Systemic Lupus Erythematosus. 62
36455951 2022
Association between the interferon-γ +874 T/A polymorphism and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis. 62
36031708 2022
New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: A case report and review of literature. 62
36246778 2022
mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus. 62
36265758 2022
High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: A possible relation to lupus nephritis. 62
36214106 2022
Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome. 62
36463907 2022
Science and visual Arts: Binomial or Dichotomy? A Pilot study in Systemic Lupus Erythematosus patients. 62
36189670 2022
Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. 62
36472065 2022
Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. 62
36471199 2022
Mitochondria as a key player in systemic lupus erythematosus. 62
35978536 2022
Altered degree centrality in patients with non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study. 62
35046118 2022
Addressing health disparities as a function of ethnicity in systemic lupus erythematosus patients. 62
36036891 2022
The association between hydroxychloroquine use and future development of systemic lupus erythematosus in patients with primary Sjögren's syndrome. 62
36089698 2022

Variations for Lupus Erythematosus

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.75 C1QA C1QB C1QC C4A C4B CR2
Show member pathways
12.4 CR2 C4B C4A C1QC C1QB C1QA
Show member pathways
12.33 CR2 C4B C1QC C1QB C1QA
Show member pathways
Show member pathways
11.79 CR2 C4B C4A C1QC C1QB C1QA
Show member pathways
11.67 CR2 C4B C4A C1QC C1QB C1QA
Show member pathways
11.58 C1QC C1QB C1QA
9 11.56 PDCD1 CR2 C4B C4A
10 11.07 CTLA4 C4B C4A C1QC C1QB C1QA
11 11.05 RASGRP1 PDCD1 CTLA4
12 10.96 CR2 C4B C1QC C1QB C1QA
13 10.86 STAT4 PTPN22 CTLA4

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.7 C4B C4A C1QC C1QB
2 complement component C1q complex GO:0062167 9.35 C1QC C1QB C1QA
3 complement component C1 complex GO:0005602 9.02 C1QC C1QB C1QA

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.2 TNFSF4 TLR5 FCGR2B CTLA4 CR2 C1QC
2 innate immune response GO:0045087 10.17 TRIM21 TLR5 CR2 C4B C4A C1QC
3 regulation of adaptive immune response GO:0002819 9.86 TNFSF4 FCGR2B
4 DNA catabolic process, endonucleolytic GO:0000737 9.85 DNASE1L3 DNASE1
5 negative regulation of immune response GO:0050777 9.85 CTLA4 FCGR2B PDCD1
6 negative regulation of B cell activation GO:0050869 9.84 FCGR2B BANK1
7 neutrophil activation involved in immune response GO:0002283 9.83 DNASE1L3 DNASE1
8 DNA catabolic process GO:0006308 9.81 DNASE1 DNASE1L3
9 negative regulation of regulatory T cell differentiation GO:0045590 9.8 CTLA4 TNFSF4
10 positive regulation of apoptotic cell clearance GO:2000427 9.78 C4A C4B
11 regulation of acute inflammatory response GO:0002673 9.73 DNASE1L3 DNASE1
12 synapse pruning GO:0098883 9.73 C1QC C1QB C1QA
13 complement activation, classical pathway GO:0006958 9.73 CR2 C4B C4A C1QC C1QB C1QA
14 regulation of neutrophil mediated cytotoxicity GO:0070948 9.71 DNASE1L3 DNASE1
15 complement activation GO:0006956 9.7 C1QA C1QB C4A C4B
16 immune system process GO:0002376 9.28 TLR5 PTPN22 PDCD1 CTLA4 CR2 C4B

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 deoxyribonuclease activity GO:0004536 9.33 DNASE1L3 DNASE1
2 complement binding GO:0001848 9.26 CR2 C4B
3 deoxyribonuclease I activity GO:0004530 8.92 DNASE1L3 DNASE1

Sources for Lupus Erythematosus

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....